专利检索 ap:("GENECRAFT INC.") AND inv:"Suk Chul Bae" 第 1 页

1.

发明授权
Adeno-associated virus complex with improved expression of RUNX3 gene and uses for preventing or treating KRAS mutated lung cancer 有权

公开(公告)号：US11767541B1

公开(公告)日：2023-09-26

申请号：US18190561

申请日：2023-03-27

申请人： GENECRAFT INC.

发明人： Suk Chul Bae , You Soub Lee , Xinzi Chi , Ja Yeol Lee

IPC分类号： C12N15/113 , C12N15/86 , A61P35/00

CPC分类号： C12N15/86 , A61P35/00 , C12N15/113 , C12N2750/14143

摘要： Provided is an adeno-associated virus (AAV) complex for expression of an RUNX3 gene including an asymmetrically modified inverted terminal repeat (ITR). The AAV complex has asymmetric ITRs in which one of the two ITRs is modified, thereby increasing self-replication efficiency in host cells and increasing expression efficiency of a delivered gene, and therefore, compared to existing AAV complexes, the AAV complex has an advantage of improved productivity and gene expression efficiency.

2.

发明授权
Modified complex platform of adeno-associated virus with improved rate of expression of loaded genes and reduced genotoxicity 有权

公开(公告)号：US11891617B1

公开(公告)日：2024-02-06

申请号：US18190630

申请日：2023-03-27

申请人： GENECRAFT INC.

发明人： Suk Chul Bae , You Soub Lee , Xinzi Chi , Tae Geun Park , Woo-Jin Kim

IPC分类号： C12N7/01 , C12N15/86

CPC分类号： C12N15/86 , C12N2750/14143 , C12N2750/14145

摘要： Described herein is an adeno-associated virus (AAV) complex platform including an asymmetrically modified inverted terminal repeat (ITR). The AAV complex has advantages of increased productivity and expression efficiency of a transgene, and decreased genotoxicity, by having an asymmetric ITR in which any one of two ITRs is modified. Also, described herein is a composition comprising the adeno-associated virus complex and a method of gene therapy.

3.

发明授权
Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof 有权

公开(公告)号：US11993783B1

公开(公告)日：2024-05-28

申请号：US18190590

申请日：2023-03-27

申请人： GENECRAFT INC.

发明人： Suk Chul Bae , You Soub Lee , Xinzi Chi , Seo Yeong Yoo , Woo-Jin Kim

IPC分类号： C12N15/864 , A61K48/00 , C12N15/113 , C12N15/86 , C12N15/90

CPC分类号： C12N15/86 , C12N15/90 , C12N2750/14122 , C12N2750/14143

摘要： Described herein is a nucleic acid molecule including an asymmetrically modified inverted terminal repeat (ITR). An AAV vector including the nucleic acid molecule has advantages of increased productivity and expression efficiency of a transgene, and decreased genotoxicity, by having an asymmetric ITR in which any one of two ITRs is modified. Also, described herein is are compositions and vectors.

4.

发明授权
Runx3 modified protein for prevention or treatment of cancer 有权

公开(公告)号：US11931401B2

公开(公告)日：2024-03-19

申请号：US17239289

申请日：2021-04-23

申请人： GeneCraft Inc.

发明人： Suk Chul Bae , Jung Won Lee , You Soub Lee

IPC分类号： A61K38/17 , A61K31/436 , A61K31/519 , A61K47/46 , A61P35/00 , C07K14/47 , C12N7/00

CPC分类号： A61K38/17 , A61K31/436 , A61K31/519 , A61K38/1709 , A61K47/46 , A61P35/00 , C07K14/4702 , C12N7/00 , C12N2750/14143

摘要： In the present invention, it was confirmed that the modified protein in which the 356th serine of Runx3 is substituted with alanine has an increased activity of maintaining the complex with Brd2 by more than 10 times compared to the wild-type Runx3, and the apoptosis effect is improved in various cancer cell lines compared to the wild-type Runx3. Therefore, the modified protein in which the 356th serine of Runx3 is substituted with an amino acid that cannot be phosphorylated by a kinase of the present invention, the polynucleotide coding thereof, the vector carrying the polynucleotide, or the virus or cell transformed with the vector can be used as a therapeutic agent for various cancers.